Paper42872079PubMed
Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway.
Cui Y and 9 others. J Geriatr Cardiol, 2026.
Cite this record
ConductScience Library. Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway. Papers, record 42872079. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42872079
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Azilsartan ameliorates angiotensin II-induced skeletal muscle atrophy via AT1R-mediated PI3K/AKT/FOXO3a signaling pathway.
- Journal
- J Geriatr Cardiol
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-15
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References32
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 41015484 | Sex-specific protective effects of angiotensin II type 1 receptor knockdown on disuse muscle atrophy in the rat soleus muscle. | J Appl Physiol (1985) | 2025 | https://conductscience.org/library/papers/41015484 | PubMed |
| 2 | 25080489 | Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase. | Am J Physiol Cell Physiol | 2014 | https://conductscience.org/library/papers/25080489 | PubMed |
| 3 | 39996717 | Withaferin A Attenuates Muscle Cachexia Induced by Angiotensin II Through Regulating Pathways Activated by Angiotensin II. | Cells | 2025 | https://conductscience.org/library/papers/39996717 | PubMed |
| 4 | 22071238 | Azilsartan medoxomil: a new Angiotensin receptor blocker. | Clin Ther | 2011 | https://conductscience.org/library/papers/22071238 | PubMed |
| 5 | 23034963 | Malnutrition self-screening by using MUST in hospital outpatients: validity, reliability, and ease of use. | Am J Clin Nutr | 2012 | https://conductscience.org/library/papers/23034963 | PubMed |
| 6 | 40151633 | Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision). | J Geriatr Cardiol | 2025 | https://conductscience.org/library/papers/40151633 | PubMed |
| 7 | 39384003 | Inhibition of TREM-1 ameliorates angiotensin II-induced atrial fibrillation by attenuating macrophage infiltration and inflammation through the PI3K/AKT/FoxO3a signaling pathway. | Cell Signal | 2024 | https://conductscience.org/library/papers/39384003 | PubMed |
| 8 | 26571361 | Angiotensin II receptor blockade promotes repair of skeletal muscle through down-regulation of aging-promoting C1q expression. | Sci Rep | 2015 | https://conductscience.org/library/papers/26571361 | PubMed |
| 9 | 32234320 | Branched-chain amino acid supplementation ameliorates angiotensin II-induced skeletal muscle atrophy. | Life Sci | 2020 | https://conductscience.org/library/papers/32234320 | PubMed |
| 10 | 16399230 | Angiotensin II directly inhibits protein synthesis in murine myotubes. | Cancer Lett | 2006 | https://conductscience.org/library/papers/16399230 | PubMed |
| 11 | 42119273 | Dysregulation of the ubiquitin-proteasome system in aging skeletal muscle. | Biomed Pharmacother | 2026 | https://conductscience.org/library/papers/42119273 | PubMed |
| 12 | 31420755 | Angiotensin II Type 1 Receptor Antagonist Azilsartan Restores Vascular Reactivity Through a Perivascular Adipose Tissue-Independent Mechanism in Rats with Metabolic Syndrome. | Cardiovasc Drugs Ther | 2019 | https://conductscience.org/library/papers/31420755 | PubMed |
| 13 | 32033882 | Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. | J Am Med Dir Assoc | 2020 | https://conductscience.org/library/papers/32033882 | PubMed |
| 14 | 38583268 | Frontiers in sarcopenia: Advancements in diagnostics, molecular mechanisms, and therapeutic strategies. | Mol Aspects Med | 2024 | https://conductscience.org/library/papers/38583268 | PubMed |
| 15 | 34389456 | Skeletal muscle atrophy: From mechanisms to treatments. | Pharmacol Res | 2021 | https://conductscience.org/library/papers/34389456 | PubMed |
| 16 | 37062187 | Azilsartan Ameliorates Skeletal Muscle Wasting in High Fat Diet (HFD)-induced Sarcopenic Obesity in Rats via Activating Akt Signalling Pathway. | Arch Gerontol Geriatr | 2023 | https://conductscience.org/library/papers/37062187 | PubMed |
| 17 | 34343333 | Azilsartan ameliorates ventricular hypertrophy in rats suffering from pressure overload-induced cardiac hypertrophy by activating the Keap1-Nrf2 signalling pathway. | J Pharm Pharmacol | 2021 | https://conductscience.org/library/papers/34343333 | PubMed |
| 18 | 35988789 | Effect of losartan treatment on Smad signaling and recovery from hindlimb unloading-induced soleus muscle atrophy in female rats. | Eur J Pharmacol | 2022 | https://conductscience.org/library/papers/35988789 | PubMed |
| 19 | 21562229 | Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21562229 | PubMed |
| 20 | 25580531 | Angiotensin II can directly induce mitochondrial dysfunction, decrease oxidative fibre number and induce atrophy in mouse hindlimb skeletal muscle. | Exp Physiol | 2015 | https://conductscience.org/library/papers/25580531 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42872079
GET https://conductscience.org/api/papers/v1/42872079/references?page=2